DiscoverMedicine via myPodCommercializing Living Therapies with CCRM: Unapproved stem cell therapies: Risks, realities and responsibilities
Commercializing Living Therapies with CCRM: Unapproved stem cell therapies: Risks, realities and responsibilities

Commercializing Living Therapies with CCRM: Unapproved stem cell therapies: Risks, realities and responsibilities

Update: 2025-01-15
Share

Description

Featuring:Paul Knoepfler, PhD, Professor of Cell Biology and Human Anatomy, UC Davis School of MedicineAmy Zarzeczny, PhD LLM, Associate Professor, Johnson Shoyama Graduate School of Public Policy, University of Regina***Unapproved stem cell therapies continue to be a significant concern in the regenerative medicine field. In this episode, Drs. Paul Knoepfler and Amy Zarzeczny discuss the issue. Listeners will hear the risks and implications of these treatments, and why they are not just...

Episode:


Podcast: https://www.ccrm.ca/

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Commercializing Living Therapies with CCRM: Unapproved stem cell therapies: Risks, realities and responsibilities

Commercializing Living Therapies with CCRM: Unapproved stem cell therapies: Risks, realities and responsibilities